1. Elanco Animal Health
Partnering for Growth
Bruce E. Taillon, PhD

5. Elanco Hybrid R&D Model
Rich
Pipeline
Elanco
Lilly
External
Successful hybrid R&D model in place for 10 years
Agnostic to R&D source
Model includes all necessary tools to access innovation

6. Elanco’s Search for Innovation The basics
Does it work?
what kind of efficacy data is available;
does it have good druggability features
Is it safe?
what kind tolerability and toxicology data is available
Can you make it?
is there line of sight towards manufacturability at a reasonable cost point

7. Large Molecules Vaccines Small Molecules Cattle Swine Poultry Fish
Elanco R&D Interests
Platform
Large Molecules Vaccines Small Molecules
Species
Food Animal
Cattle Swine Poultry Fish
Companion Animal
Dogs Cats
Respiratory
Enteric
Mastitis
Metabolic
Parasiticide
Parasiticide
Dermatology
Pain/Osteoarthritis
Cardiovascular
Diabetes, Oncology
CKD, IBD
Unmet Needs

8. Elanco’s TCMR Approach
Translational Comparative Medical Research (TCMR Group)
Working hypothesis:
The probability of technical success for the delivery of safe and efficacious human and veterinary therapeutics will improve for innovative molecules by testing early in spontaneous veterinary animal disease trials
Allows for the translational of innovation between animal and human health
Prerequisites:
Connective hypothesis between Companion Animal outcomes and Human targeted indication
A relevant spontaneously occurring disease in Companion Animals exists
Cost and speed effective compared to human trial

9. Why Elanco Invests in TCMR
Science wins
Understanding assets
Understanding disease
Patients win
Safer clinical trials
Increased probability of technical success
Owners/Pets win
Access to care
Investment in the future

10. Translational Approach: Opportunities
A translational approach is a two way street between Animal health and Human health
Beyond the science, a successful relationship will rely on animal health inherent advantages
Human
Animal
Multiple Species Studies
Direct to target species
Cost: >$1 B per NME
Cost: <$100M per NME
Devt Time: years
Devt Time: 5-8 years
Blockbuster: >$1B
Blockbuster: >$100M

11. Translational Approach: Trends
: Increasing awareness of the Animal Health importance attracts interest to the veterinary field
Veterinary companies have been more innovative than ever
First in class drugs have reached the animal health market before the human market. Example: EP4 antagonist for OA Pain
Cost of biologics platform (mAb, proteins) has significantly decreased for use in veterinary medicine
Elanco Imrestor: an immunomodulator, bovine granulocyte stimulating factor for the reduction of incidence of clinical mastitis
Veterinary monoclonal antibody have reached the market for companion animal dermatology